Lowenstein Reps BASF In Deal For Biotech Co. Verenium
Verenium has about 12.8 million shares outstanding, which would value the deal at about $51 million. The deal is expected to close in the fourth quarter of 2013. The acquisition will bolster BASF’s role in the efficient enzyme space, according to a statement issued by BASF.
“Combining Verenium’s scientific and technological excellence with BASF’s enzyme activities and its...
To view the full article, register now.